937063-34-8

Basic information

• Product Name: methyl morpholine-2-carboxylate hydrochloride
• Synonyms: methyl morpholine-2-carboxylate hydrochloride;2-Morpholinecarboxylic acid methyl ester hydrochloride (1:1);2-Morpholinecarboxylic acid methyl ester HCl
• CAS NO: 937063-34-8
• Molecular Formula: C₆H₁₁NO₃*ClH
• Molecular Weight: 181.61738
• Mol File: 937063-34-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: methyl morpholine-2-carboxylate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: methyl morpholine-2-carboxylate hydrochloride(937063-34-8)
• EPA Substance Registry System: methyl morpholine-2-carboxylate hydrochloride(937063-34-8)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 937063-34-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl morpholine-2-carboxylate hydrochloride is used as a key intermediate in the synthesis of chromen-4-one derivatives for the treatment of hepatitis B virus infection. Its unique chemical properties allow for the development of novel antiviral agents that can target and combat the hepatitis B virus, offering potential therapeutic benefits for patients suffering from this condition.

Upstream product

• 67-56-1 methanol 
• 300582-83-6 2-carboxymorpholine acid 
• 500789-41-3 4-(t-butyloxycarbonyl)morpholine-2-carboxylic acid methyl ester 
• 189321-66-2 4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid 

Downstream Products

• 937060-13-4 methyl 4-{3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl}-2-morpholinecarboxylate 

Relevant articles and documents

COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS

The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).

Discovery of novel tricyclic compounds as squalene synthase inhibitors

In the present article, we have reported the design, synthesis, and identification of highly potent benzhydrol derivatives as squalene synthase inhibitors (compound 1). Unfortunately, the in vivo efficacies of the compounds were not enough for acquiring the clinical candidate. We continued our investigation to obtain a more in vivo efficacious template than the benzhydrol template. In our effort, we focused on a benzoxazepine ring and designed a new tricyclic scaffold by the incorporation of heterocycle into it. Prepared pyrrolobenzoxazepine derivatives showed further efficient in vitro and in vivo activities.